evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

26 questions · 28 findings · 12 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 6 · 21.4%GRADE not reported 2 · 7.1%Very low 7 · 25%Low 12 · 42.9%Moderate 1 · 3.6%High 0 · 0%

Low molecular weight heparin vs vitamin K antagonist secondary prophylaxis

All‐cause mortality (main analysis ‐ active cancer) · patients with cancer with venous thromboembolism

Low molecular weight heparin secondary prophylaxis showed no clear difference in all‐cause mortality (main analysis ‐ active cancer) compared with vitamin K antagonist secondary prophylaxis (low certainty).

1 finding from 1 review

Direct thrombin inhibitors vs low molecular weight heparin

All‐cause Mortality events · patients with prevention of venous thromboembolism following total hip or knee replacement

Direct thrombin inhibitors probably leads to higher all‐cause Mortality events compared with low molecular weight heparins (moderate certainty).

1 finding from 1 review

Aspirin vs low molecular weight heparin

All‐cause mortality · ambulatory patients with multiple myeloma receiving immunomodulatory agents

It is very uncertain whether aspirin (ASA) changes all‐cause mortality compared with low molecular weight heparin (LMWH) (very low certainty).

2 findings from 1 review

Vitamin K antagonists vs low molecular weight heparin

All‐cause mortality · ambulatory patients with multiple myeloma receiving immunomodulatory agents

It is very uncertain whether vitamin K antagonist (VKA) changes all‐cause mortality compared with low molecular weight heparin (LMWH) (very low certainty).

2 findings from 1 review

Direct oral anticoagulant secondary prophylaxis vs Low molecular weight heparin secondary prophylaxis

All‐cause mortality · patients with cancer with venous thromboembolism

Direct oral anticoagulant secondary prophylaxis showed no clear difference in all‐cause mortality compared with low molecular weight heparin secondary prophylaxis (low certainty).

1 finding from 1 review

Direct thrombin inhibitors vs vitamin K antagonist (VKA)

All‐cause Mortality events in TKR combined doses · patients with prevention of venous thromboembolism following total hip or knee replacement

Direct thrombin inhibitors showed no clear difference in all‐cause Mortality events in TKR combined doses compared with vitamin K antagonists (low certainty).

1 finding from 1 review